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Substantial amounts of platelet-activating factor (PAF) were formed when IysoPAF was mixed with aspirin (e.g. 0.04% of added IysoPAF (200 
nmol) was converted to PAF when mixed with aspirin (2 pmol) for 1 h). Non-enzymatic formation of PAF from aspirin and 1ysoPAF also occurs 
in the aqueous olution or in organic solvents in time-dependent and dose-dependent manners. Possible meanings of the non-enzymatic formation 
of PAF are discussed. 
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1. INTRODUCTION 
Platelet-activating factor (PAF) is a potent bioactive 
lipid molecule, the structure of which was finally eluci- 
dated as 1 -O-alkyl-2-acetyl-sn-glycero-3-phosphocholine 
in 1979 [l-3]. PAF is known to cause a variety of biolo- 
gical responses, such as the aggregation and degranula- 
tion of platelets and polymorphonuclear leukocytes, 
smooth muscle contraction, increased vascular permea- 
bility, hypotension, gastric ulcer and increased bron- 
chohyper-reactivity. It has been postulated that PAF is 
implicated in the pathogenesis of various allergic and 
inflammatory diseases, such as endotoxin shock, an- 
aphylactic shock, nephritis and bronchial asthma [4,5]. 
Several investigators have also suggested that PAF is an 
important bioactive molecule in several physiological 
processes, such as pregnancy [4,5]. 
Recently, we investigated the levels of PAF-like lipid 
in various multicellular invertebrates [6,7]. We found 
that PAF-like lipid is widely distributed in various lower 
order animals, which are usually enriched in alkyl ether 
phospholipids as well. It seems very likely that PAF 
plays physiologically important roles even in these 
lower order animals. In an extended study, we also 
noticed that a commercial Japanese antifebrile medicine 
(Mimizu Ippuh San, a mixture of the extract of earth- 
worms, aspirin, acetaminophen and caffeine; Tenshindo 
Co., Nara, Japan) contains an extremely high level (per 
lipid phosphorus) of PAF-like material (Sugiura, T., 
unpublished data). This observation was very curious 
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and unexpected, because either living or dried earth- 
worms themselves contain a lesser amount of PAF-like 
material. We then tried to explain how a PAF-like ma- 
terial came to be included in this antifebrile medicine. 
Finally, we reached the conclusion that PAF is formed 
from 1ysoPAF through non-enzymatic transfer of the 
acetyl moiety from aspirin based on the facts that earth- 
worms contain a large amount of 1ysoPAF (2% total 
phospholipids; Sugiura, T., unpublished data) and aspi- 
rin is known to act as an acetyl donor in the non- 
enzymatic acetylation of proteins such as cyclooxyge- 
nase [S]. 
In this study, we examined this possibility precisely. 
We confirmed that a large amount of PAF is actually 
formed from 1ysoPAF and aspirin in a non-enzymatic 
manner. The reaction proceeds either in the presence or 
absence of aqueous solution. Possible implications of 
the non-enzymatic formation of PAF or PAF-like mate- 
rials are also discussed. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
LysoPAF (I-O-hexadecyl) was purchased from Novabiochem 
(Laufelfingen, Switzerland). PAF (I-O-hexadecyl) was obtained from 
Bachem (Bubendorf, Switzerland). Aspirin (acetylsalicylic acid) and 
acetic acid were from Wako Pure Chem. Ind. (Osaka, Japan). Essen- 
tially fatty acid-free bovine serum albumin (BSA) was from Sigma (St. 
Louis, MO). Pre-coated silica gel TLC plates were purchased from 
Merck (Darmstadt, Germany). The specific PAF antagonists, CV6209 
and TCV309, were generous gifts from Takeda Chem. Ind. (Osaka, 
Japan). 
2.2. Non-enzymatic formation of PAF 
LysoPAF (200 nmol) dissolved in 100 ~1 of chlorofornnmethanol 
(2: 1, v/v) and aspirin (2 pmol) dissolved in10 ~1 of acetone were mixed 
in a round-bottomed glass tube and organic solvents were quickly 
removed under a stream of nitrogen. The residue was left at room 
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temperature for l-24 h. Then 2 ml of 0.25% BSA-containing HEPES- 
Tyrode’s solution was added to the residue and vortexed, and the 
solution was further diluted with the same buffer. A portion of the 
diluted solution (2.5 ~1) was taken and added to 225 ~1 of washed rabbit 
platelet suspension (in 5 mM HEPES-Tyrode’s buffer). The aggrega- 
tion of washed rabbit platelets by samples and by standard PAF was 
recorded in a haematracer (Niko PAT 2 M), as described previously 
[9]. The amount of PAF formed through non-enzymatic acetylation 
was estimated using a calibration curve with standard PAF. In this 
case, the final concentration of 1ysoPAF in each cuvette, either for 
sample or for standard PAF, was fixed to 1 ,uM, which is not sufficient 
per se to induce aggregation, in order to minimize the difference in 
conditions between tubes. In a separate xperiment, the residue was 
dissolved in a small amount of chloroform:methanol (2:1, v/v) and 
immediately applied to a TLC plate. The TLC plate was developed 
with chloroform:methanol:water (65:35:6, v/v) and the silica gel was 
zonally scraped (2 cm width). Lipids were extracted from the silica gel 
by the method of Bligh and Dyer [lo] and subjected to bioassay. In 
order to examine whether PAF is formed in aqueous solution, ly- 
soPAF (final 100 PM) and aspirin (1 mM) were incubated in sterile 
5 mM HEPES-buffered saline (pH 7.4) at 37°C for 3-24 h. After 
standing for several hours, a portion of the reaction mixture was taken 
and added to the rabbit platelet suspension. The amounts of formed 
PAF were determined as described above. 
3. RESULTS AND DISCUSSION 
First, we examined whether PAF is formed from ly- 
soPAF and aspirin in tubes in which aqueous solution 
is absent. As demonstrated in Fig. Ic, a strong platelet- 
aggregating activity was detected in tubes where ly- 
soPAF and aspirin were mixed and dried together (the 
molar ratio of 1ysoPAF to aspirin was 1: 10). On the 
other hand, negligible activity was detected in the cases 
where either aspirin alone (Fig. la) or 1ysoPAF alone 
(Fig. lb) was employed. This observation indicates that 
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Fig. 1. Aggregation of washed rabbit platelets by PAF-like material 
formed upon mixing of 1ysoPAF with aspirin. Platelets were chal- 
lenged with (a) aspirin alone; (b) 1ysoPAF alone; (c) the sample ob- 
tained after mixing of 1ysoPAF and aspirin for 1 h; (d) platelets were 
treated with CV6209 (1 ,uM) 1 min prior to the addition of the same 
sample in (c); (e) platelets were treated with TCV309 (1 ,uM) 1 min 
prior to the addition of the same sample in c. 
Fig. 2. TLC separation of PAF-like material formed upon mixing of 
1ysoPAF with aspirin. LysoPAF (200 nmol) and aspirin (2 pmol) were 
mixed and dried for 1 h. Then the residue was dissolved in chloro- 
fotmmethanol(2: 1, v/v) and immediately applied to a TLC plate. The 
silica gel plate was developed with chloroform:methanol:water 
(65:35:6, v/v) and zonally scraped (2 cm width). The ability of each 
fraction to aggregate washed rabbit platelets was examined as 
described in section 2. 
a material with platelet-aggregating activity was formed 
from 1ysoPAF and aspirin after mixing. 
The effects of PAF antagonists were then examined. 
Here we used two types of potent and specific PAF 
antagonists with different chemical structures (CV6209 
and TCV309). As depicted in Fig. Id and e, the pre- 
treatment of platelets with either CV6209 or TCV309 
completely blocked the aggregation induced by the sam- 
ple. This suggests that the bioactive material produced 
after mixing of 1ysoPAF with aspirin is PAF itself, 
which was further confirmed by TLC analysis. The ac- 
tivity co-migrated with authentic PAF and no activity 
was detected in other fractions (Fig. 2). Hence, it is 
apparent that PAF is actually formed from 1ysoPAF 
and aspirin by a non-enzymatic transacetylation reac- 
tion. As shown in Fig. 3, the amounts of PAF increased 
with time, although the rates of the formation some- 
what gradually decreased. About 0.04% and 0.15% of 
added 1ysoPAF (total 200 nmol) was converted to PAF 
after 1 h and 24 h, respectively. 
Next we examined whether PAF is formed from ly- 
soPAF and aspirin in the presence of aqueous solution. 
Fig. 4 demonstrates the formation of PAF in HEPES- 
buffered saline (pH 7.4) as a function of time. We con- 
firmed that the formation of PAF takes place even in 
aqueous solution. The amounts of PAF increased al- 
most linearly with time at least up to 24 h. The effect 
of varying concentrations of aspirin and IysoPAF on 
the formation of PAF is shown in Fig. 5. The amounts 
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Fig. 3. Formation of PAF upon mixing of 1ysoPAF with aspirin as a 
function of time. LysoPAF (200 nmol) and aspirin (2 pmol) were 
mixed and dried for the indicated periods. Then 2 ml of 0.25% BSA- 
containing HEPES-Tyrode’s solution was added to the tubes. The 
amounts of PAF were estimated using washed rabbit platelets as 
described in section 2. Values are the means rt SD. from three deter- 
minations. 
of PAF increased with increased concentrations of aspi- 
rin (A) and IysoPAF (B). The levels of PAF synthesized 
during the incubation in the aqueous solution seem to 
be fairly high. For instance, as up to 17.7 nM (final 
concentration in tubes) PAF was produced when 100 
,uM 1ysoPAF and 10 mM aspirin were incubated to- 
gether; that is, 0.018% of existing 1ysoPAF was con- 
verted to PAF. We also observed that such non-enzy- 
matic formation of PAF occurs in organic solvents such 
as ethanol, the rate being somewhat higher than that in 
the aqueous solution (data not shown). Thus, the con- 
tact of 1ysoPAF with aspirin in either aqueous solution 
or organic solvents is sufficient to induce the formation 
of appreciable amounts of PAF. In contrast to the case 
of aspirin, only a trace amount of PAF was produced 
when 1ysoPAF was incubated with 100 mM acetic acid 
for several days (data not shown), although considera- 
ble amounts of PAF were formed when 1ysoPAF was 
treated with glacial acetic acid (0.007% of added ly- 
soPAF was converted to PAF during 1 h treatment). In 
any case, it is apparent that the acetyl moiety is directly 
transferred from aspirin to 1ysoPAF through a non- 
enzymatic process in the case of aspirin-induced PAF 
formation even in an aqueous solution. 
Among various non-steroidal anti-inflammatory 
drugs, aspirin has a unique characteristic for transfer- 
ring its acetyl moiety to other molecules. Various types 
of proteins are known to undergo non-enzymatic acetyl- 
ation when treated with aspirin [11,12]. The acetylation 
of cyclooxygenase is of particular importance, because 
the acetylation of the enzyme protein results in complete 
loss of the enzyme activity [8]. In the case of cyclooxyge- 
nase, the hydroxy group of the serine residue is selec- 
tively acetylated by aspirin in a non-enzymatic manner 
[ 131. Such irreversible inactivation of cyclooxygenase is 
responsible, at least in part, for the anti-inflammatory 
effects of aspirin observed in vivo. 
Here we demonstrated that 1ysoPAF is also acetyl- 
ated by aspirin to form PAF. Such a reaction takes 
place either in the presence or absence of an aqueous 
solution or organic solvent. To our knowledge, this is 
the first report on the non-enzymatic formation of PAF 
from aspirin and 1ysoPAF. In view of the facts that 
aspirin is very commonly used in medication and that 
PAF has powerful and diverse biological activities, it 
seems important to examine whether such non-enzy- 
matic formation of PAF occurs under various circum- 
stances. We observed that a commercial antifebrile 
drug, Mimizu Ippuh San, contains a considerable 
amount of PAF in addition to 1ysoPAF and aspirin. It 
seems very likely that most of the PAF present in this 
drug was formed from 1ysoPAF and aspirin through the 
non- enzymatic process described here. 
On the other hand, it is not clear at present that 
non-enzymatic formation of PAF from 1ysoPAF and 
aspirin takes place even in vivo. Blood plasma is known 
to contain relatively high levels of lysophosphati- 
dylcholine (1ysoPC) (e.g. 130 nmol/ml, for rabbit 
plasma; Mabuchi-Itoh, K., unpublished result) which is 
assumed to be formed in large part through the action 
of 1ecithin:cholesterol acetyltransferase [14] and is usu- 
ally composed of 1-acyl species [15]. Therefore, the l- 
acyl analogue of PAF, which is known to be able to 
prime human neutrophils [16], may be produced if 
1ysoPC has a chance to contact aspirin. In this case, the 
influence of serum proteins and serum lipids on the 
reaction should be carefully taken into consideration, 
because these other materials may interfere with the 
reaction to some extent. 
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Fig. 4. Formation of PAF upon mixing of IysoPAF with aspirin in 
HEPES-buffered saline as a function of time. LysoPAF (1OOpM) and 
aspirin (1 mM) were incubated in 0.4 ml of 5 mM HEPES-buffered 
saline @H 7.4) at 37°C for the indicated periods. A portion of the 
mixture was then taken and added to washed rabbit platelets. The 
amounts of PAF were estimated as described in section 2. Values are 
the means f S.D. from three determinations. 
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Fig. 5. Effects of different concentrations of aspirin (A) and IysoPAF (B) on the non-enzymatic formation of PAF. (A) Aspirin (O-10 mM) was 
incubated with IysoPAF (100 PM) in 0.4 ml of 5 mM HEPES-buffered saline (pH 7.4) at 37°C for 24 h. (B) LysoPAF (&l mM) was incubated 
with aspirin (1 mM) in the same buffer for 24 h. The amounts of PAF were estimated as described in section 2. Values are the means ? SD. from 
three determinations. 
Another possibility may lie in the case of the digestive 
system. Food-derived phospholipids are subjected to 
hydrolysis by phospholipases uch as pancreatic phos- 
pholipase A,. Such reactions could result in the forma- 
tion and accumulation of lysophospholipids in the di- 
gestive system. If foods contain high levels of alkyl 
ether-containing PC, such as sea foods, including sea 
cucumbers, sea urchins and shellfish etc. [6,7], large 
amounts of 1ysoPAF may be generated during diges- 
tion. Therefore, a simultaneous intake of aspirin and 
foods enriched in alkyl ether-containing PC may result 
in the formation of PAF, even if it occurs transiently, 
in the digestive system. Thus, further detailed studies 
are indispensable to clarify whether non-enzymatic for- 
mation of PAF from 1ysoPAF and aspirin is actually of 
practical importance from pharmaceutical and pharma- 
cological viewpoints. 
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